{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:54:03Z","timestamp":1771574043365,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BeiGene, Ltd","award":["BeiGene, Ltd"],"award-info":[{"award-number":["BeiGene, Ltd"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The EORTC QLQ-OES18 has previously demonstrated clinical validity; however, there are limited published psychometric data for patients with advanced esophageal squamous cell carcinoma (ESCC). We evaluated the measurement properties of the QLQ-OES18 in a clinical trial population of patients with advanced or metastatic ESCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methodology<\/jats:title>\n            <jats:p>Analyses used data from RATIONALE 302 (NCT03430843), a randomized phase 3 study of tislelizumab versus investigator-chosen chemotherapy as second-line treatment for patients with advanced or metastatic ESCC. Psychometric validation of the QLQ-OES18 included tests of reliability, construct validity, ability to detect change, and estimation of anchor-based meaningful within-patient change (MWPC) thresholds\u2014the latter two being exploratory given that the trial was not powered to detect efficacy in patient-reported outcome endpoints.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In total, 512 patients were randomized to either tislelizumab or chemotherapy; the average age was 61.5 years, and 84.4% were male. Three of the 4 QLQ-OES18 multi-item scales (dysphagia, eating, and pain) and the index scale met the prespecified criterion for acceptable internal consistency as well as acceptable test-retest reliability. Associations between baseline QLQ-OES18 scores and convergent\/discriminant validators were generally as expected (i.e., the QLQ-OES18 pain score had a strong positive correlation with the QLQ-C30 pain score). For known-groups validity, 88.6% of analyses demonstrated the hypothesized direction of effect, suggesting that the expected differences in baseline QLQ-OES18 scores between prespecified groups were observed. Ability to detect change analyses indicated that several QLQ-OES18 domain scores demonstrated sensitivity in detecting possible treatment effects, although many patients reported minimal symptoms at baseline, which limited the ability to detect significant improvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Overall, a collection of psychometric evidence indicated that the EORTC QLQ-OES18 reliably and validly measured symptom severity in the RATIONALE 302 population. Specifically, the dysphagia domain consistently demonstrated robust psychometric properties. Limitations in data reduced the interpretability of MWPC thresholds and are discussed in detail.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41687-025-00891-4","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T09:40:21Z","timestamp":1747820421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Psychometric validation of the EORTC QLQ-OES18 in patients with advanced or metastatic esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"9","author":[{"given":"Lauren","family":"Podger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boxiong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5702-2903","authenticated-orcid":false,"given":"Gisoo","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"1","key":"891_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1186\/s12885-021-09007-9","volume":"21","author":"B Sunde","year":"2021","unstructured":"Sunde B, Lindblad M, Malmstr\u00f6m M, Hedberg J, Lagergren P, Nilsson M (2021) Health-related quality of life one year after the diagnosis of oesophageal cancer: a population-based study from the Swedish National Registry for Oesophageal and Gastric Cancer. BMC Cancer 21(1):1277","journal-title":"BMC Cancer"},{"key":"891_CR2","doi-asserted-by":"crossref","unstructured":"Davis LE, Gupta V, Allen-Ayodabo C, Zhao H, Hallet J, Mahar AL et al (2020) Patient-reported symptoms following diagnosis in esophagus cancer patients treated with palliative intent. Dis Esophagus 33(8)","DOI":"10.1093\/dote\/doz108"},{"key":"891_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2147\/CLEP.S166078","volume":"10","author":"QL Wang","year":"2018","unstructured":"Wang QL, Xie SH, Wahlin K, Lagergren J (2018) Global time trends in the incidence of esophageal squamous cell carcinoma. Clin Epidemiol 10:717\u2013728","journal-title":"Clin Epidemiol"},{"issue":"4","key":"891_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/JCO.21.00601","volume":"40","author":"A Adenis","year":"2022","unstructured":"Adenis A, Kulkarni AS, Girotto GC, de la Fouchardiere C, Senellart H, van Laarhoven HWM et al (2022) Impact of pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal Cancer on Health-Related quality of life in KEYNOTE-181. J Clin Oncol 40(4):382\u2013391","journal-title":"J Clin Oncol"},{"key":"891_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejca.2018.07.132","volume":"103","author":"E Ter Veer","year":"2018","unstructured":"Ter Veer E, van Kleef JJ, Schokker S, van der Woude SO, Laarman M, Haj Mohammad N et al (2018) Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis. Eur J Cancer 103:214\u2013226","journal-title":"Eur J Cancer"},{"issue":"6","key":"891_CR6","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s10120-021-01209-1","volume":"24","author":"JJ van Kleef","year":"2021","unstructured":"van Kleef JJ, Dijksterhuis WPM, van den Boorn HG, Prins M, Verhoeven RHA, Gisbertz SS et al (2021) Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study. Gastric Cancer 24(6):1203\u20131212","journal-title":"Gastric Cancer"},{"issue":"6","key":"891_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z et al (2020) Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 21(6):832\u2013842","journal-title":"Lancet Oncol"},{"issue":"11","key":"891_CR8","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K et al (2019) Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(11):1506\u20131517","journal-title":"Lancet Oncol"},{"issue":"35","key":"891_CR9","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH et al (2020) Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 38(35):4138\u20134148","journal-title":"J Clin Oncol"},{"issue":"10","key":"891_CR10","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/S0959-8049(03)00270-3","volume":"39","author":"JM Blazeby","year":"2003","unstructured":"Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M et al (2003) Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer 39(10):1384\u20131394","journal-title":"Eur J Cancer"},{"issue":"1","key":"891_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139\u2013144","journal-title":"J Clin Oncol"},{"issue":"13","key":"891_CR12","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","volume":"44","author":"K Cocks","year":"2008","unstructured":"Cocks K, King MT, Velikova G, Fayers PM, Brown JM (2008) Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer 44(13):1793\u20131798","journal-title":"Eur J Cancer"},{"key":"891_CR13","unstructured":"Food and Drug Administration (FDA) (2022) Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. https:\/\/www.fda.gov\/media\/159500\/download"},{"key":"891_CR14","unstructured":"Food and Drug Administration (FDA) (2023) Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making. https:\/\/www.fda.gov\/media\/166830\/download"},{"issue":"26","key":"891_CR15","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z et al (2022) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): A randomized phase III study. J Clin Oncol 40(26):3065\u20133076","journal-title":"J Clin Oncol"},{"issue":"5","key":"891_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"891_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/BF00439229","volume":"5","author":"MT King","year":"1996","unstructured":"King MT (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5(6):555\u2013567","journal-title":"Qual Life Res"},{"key":"891_CR18","doi-asserted-by":"publisher","unstructured":"Petersen JH. (2001) Quality of Life. Assessment, Analysis and Interpretation., Fayers PM, Machin D (2000) Wiley, Chichester, ISBN 0-471-96861-7. Statistics in Medicine 20(14):2214\u20132216 https:\/\/doi.org\/10.1002\/sim.941","DOI":"10.1002\/sim.941"},{"issue":"3","key":"891_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/00273170802285941","volume":"43","author":"L Wang","year":"2008","unstructured":"Wang L, Zhang Z, McArdle JJ, Salthouse TA (2008) Investigating ceiling effects in longitudinal data analysis. Multivar Behav Res 43(3):476\u2013496","journal-title":"Multivar Behav Res"},{"issue":"3","key":"891_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02310555","volume":"16","author":"LJ Cronbach","year":"1951","unstructured":"Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16(3):297\u2013334","journal-title":"Psychometrika"},{"issue":"2","key":"891_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420\u2013428. https:\/\/doi.org\/10.1037\/0033-2909.86.2.420","journal-title":"Psychol Bull"},{"key":"891_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","volume":"1","author":"KO McGraw","year":"1996","unstructured":"McGraw KO, Wong SP (1996) Forming inferences about some intraclass correlation coefficients. Psychol Methods 1:30\u201346. https:\/\/doi.org\/10.1037\/1082-989X.1.1.30","journal-title":"Psychol Methods"},{"issue":"1","key":"891_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J et al (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60(1):34\u201342","journal-title":"J Clin Epidemiol"},{"key":"891_CR24","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum Associates, Hillsdale, NJ","edition":"2"},{"issue":"6","key":"891_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"891_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1037\/1082-989X.8.4.434","volume":"8","author":"S Olejnik","year":"2003","unstructured":"Olejnik S, Algina J (2003) Generalized eta and omega squared statistics: measures of effect size for some common research designs. Psychol Methods 8(4):434\u2013447","journal-title":"Psychol Methods"},{"issue":"2","key":"891_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2333\/bhmk.40.129","volume":"40","author":"K Okada","year":"2013","unstructured":"Okada K (2013) Is omega squared less biased?? A comparison of three major effect size indices in one-way anova. Behaviormetrika 40(2):129\u2013147","journal-title":"Behaviormetrika"},{"issue":"9 Suppl","key":"891_CR28","first-page":"Ii84","volume":"38","author":"MH Liang","year":"2000","unstructured":"Liang MH (2000) Longitudinal construct validity: establishment of clinical meaning in patient evaluative instruments. Med Care 38(9 Suppl):Ii84\u201390","journal-title":"Med Care"},{"key":"891_CR29","unstructured":"Hinkle D, Wiersma W, Jurs S (2003) Applied statistics for the behavioral sciences, 5th edn. Houghton Mifflin"},{"key":"891_CR30","unstructured":"Food and Drug Administration (FDA) (2018) Patient Focused Drug Development 3: Methods to Identify What is Important to Patients & Select, Develop or Modify Fit-for-Purpose Clinical Outcomes Assessments. https:\/\/www.fda.gov\/media\/116277\/download"},{"issue":"5","key":"891_CR31","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s11136-022-03181-4","volume":"32","author":"K Cocks","year":"2023","unstructured":"Cocks K, Buchanan J (2023) How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales. Qual Life Res 32(5):1247\u20131253","journal-title":"Qual Life Res"},{"issue":"8","key":"891_CR32","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s11136-010-9675-8","volume":"19","author":"WC Chie","year":"2010","unstructured":"Chie WC, Tsai CJ, Chiang C, Lee YC (2010) Quality of life of patients with oesophageal cancer in Taiwan: validation and application of the Taiwan Chinese (Mandarin) version of the EORTC QLQ-OES18: a brief communication. Qual Life Res 19(8):1127\u20131131","journal-title":"Qual Life Res"},{"issue":"10","key":"891_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox046","volume":"30","author":"Z Dai","year":"2017","unstructured":"Dai Z, Lang W, Yang H, Tian J, Sun W, Pekbay B et al (2017) Validation of EORTC QLQ-OES18 for Chinese patients with esophageal cancer. Dis Esophagus 30(10):1\u20137","journal-title":"Dis Esophagus"},{"issue":"7","key":"891_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/jjco\/hyw040","volume":"46","author":"T Fujita","year":"2016","unstructured":"Fujita T, Okada N, Sato T, Mayanagi S, Kanamori J, Daiko H (2016) Translation, validation of the EORTC esophageal cancer quality-of-life questionnaire for Japanese with esophageal squamous cell carcinoma: analysis in thoraco-laparoscopic esophagectomy versus open esophagectomy. Jpn J Clin Oncol 46(7):615\u2013621","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"891_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.7314\/APJCP.2015.16.1.45","volume":"16","author":"Y Wen","year":"2015","unstructured":"Wen Y, Pan XF, Huang WZ, Zhao ZM, Wei WQ, Chen F et al (2015) Quality of life for patients with esophageal\/gastric cardia precursor lesions or cancer: a one-year prospective study. Asian Pac J Cancer Prev 16(1):45\u201351","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"891_CR36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/2168479015622667","volume":"50","author":"CD Coon","year":"2016","unstructured":"Coon CD, Cappelleri JC (2016) Interpreting change in scores on patient-reported outcome instruments. Ther Innov Regul Sci 50(1):22\u201329","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"891_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/ajco.12070","volume":"10","author":"G Bedard","year":"2014","unstructured":"Bedard G, Zeng L, Zhang L, Lauzon N, Holden L, Tsao M et al (2014) Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer. Asia Pac J Clin Oncol 10(2):109\u2013117","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00891-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T09:40:24Z","timestamp":1747820424000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-025-00891-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00891-4","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"23 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in accordance with Good Clinical Practice guidelines of the International Conference on Harmonization, the principles of the Declaration of Helsinki, and local laws and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent prior to participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LP and DS received consulting fees for study data analyses and reporting from BeOne Medicines Ltd. LL, LZ, BT, and GB are employees of BeOne Medicines Ltd.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}